INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY), Thursday announced topline results from SURPASS-CVOT, evaluating the efficacy and safety of Mounjaro compared with Trulicity in adults with type 2 diabetes and established atherosclerotic cardiovascular disease.
The randomized, double-blind, parallel group Phase 3 trial showed that Mounjaro achieved the primary objective by demonstrating a non-inferior rate of major adverse cardiovascular events.
Additionally, Mounjaro showed improvements on key measures of A1C, weight, renal function and all-cause mortality.
Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, commented, 'These findings strengthen the case for Mounjaro as a potential front-line treatment for people with type 2 diabetes and cardiovascular disease.'
The company plans to submit these data to global regulatory authorities by the end of 2025.
In the pre-market hours, LLY is trading at $750.86, down 1.48 percent on the New York Stock Exchange.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
